Form 4: Trevi Therapeutics Director Granted 45,000 Stock Options

Dominick Colangelo, a Director at Trevi Therapeutics, Inc. (TRVI), was granted 45,000 nonstatutory stock options with an exercise price of $6.25 per share.

Summary

• Dominick Colangelo, a Director of Trevi Therapeutics, Inc. (TRVI), was granted 45,000 nonstatutory stock options.
• The options have an exercise price of $6.25 per share.
• The grant date for these options was June 11, 2025.
• The options are scheduled to fully vest on the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Mr. Colangelo's continued service as a director, employee, or consultant of the Issuer.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Dominick Colangelo beneficially owns 45,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as the stock option grant aligns director incentives with shareholder interests, which is generally viewed favorably. However, it's a routine compensation event and does not indicate significant new positive developments for the company's operations or financials.

Positives

• The grant of stock options to a director aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule encourages continued service and commitment from the director.

Negatives

• No direct negative financial impacts are immediately apparent from this stock option grant, as it is a standard compensation mechanism.

Risks

• The value of the stock options is subject to the future performance of Trevi Therapeutics' common stock; if the stock price does not exceed the exercise price of $6.25, the options may expire worthless.
• Vesting is subject to continued service, meaning the options could be forfeited if the director's service ceases before vesting.

Future Outlook

The document primarily details a past (or future, based on the grant date) insider transaction and does not provide a general future outlook or guidance for the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction. Stock option grants are a common form of compensation for directors in the biotechnology and pharmaceutical industries, aiming to align their interests with long-term company performance and shareholder value creation. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The stock option grant to Dominick Colangelo, a Director, is a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases above the exercise price.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Management: The grant is part of the compensation structure for a director, reinforcing their commitment to the company's long-term success.

Next Steps

• The options are scheduled to vest on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders following the grant date, subject to continued service.

Key Dates

Keywords

Trevi Therapeutics, TRVI, Stock Options, SEC Form 4, Insider Transaction, Director Compensation, Equity Grant, Nonstatutory Stock Option